Notícias

Novo Nordisk (NYSE:NVO)'s majority owner has launched a large pan European research program focused on obesity and cardiometabolic diseases. The initiative aims to speed up research, support startups, and feed potential candidates into Novo Nordisk's future drug pipeline. Pfizer is expanding efforts in obesity treatments, including plans for a first in class monthly GLP 1 therapy and broader clinical trials. Novo Nordisk is a central player in obesity and diabetes care, and this new...

Novo Nordisk Foundation has launched CardioMetabolic Bridge, a pan-European initiative focused on translating cardiometabolic research into commercial therapies. The program targets new treatments for obesity, diabetes, and cardiovascular disease, with funding spread over six years and across multiple European countries. The effort aims to move early-stage academic work closer to clinical testing and potential commercial use. Novo Nordisk (CPSE:NOVO B) enters this development with the stock...

Novo Nordisk has been telling investors that volume will eventually offset price cuts, and early results suggest investors should listen.

With GLP-1 usage continuing to rise, a group of unlikely beneficiaries is emerging; stocks in the broader health care sector and even in retail could stand out.

Novo Nordisk Owner Bets Big on Obesity Breakthroughs With New $69 Million Program

Novo Nordisk Foundation commits up to EUR 60 million for drug discovery projects

Deutsche Bank expects Novo Nordisk's (NYSE:NVO) pending ZEUS trial to miss, but sees limited upside even if the drug proves successful, given the company's looming patent cliff. The analyst has set a target of DKK290, just 3.6% above the last closing price of DKK280.10, and maintains a hold...

The foundation behind Novo Nordisk is funding a new effort to turn scientific discoveries into treatments.

June 19 (Reuters) - European shares inched higher on Friday, aided by gains in energy and healthcare stocks as investors remained cautious after U.S.-Iran negotiations to end the Middle conflict

By Stella Qiu SYDNEY, June 19 (Reuters) - Asian shares reversed course and fell on Friday as investors took some money off the table from record rallies in Japan and South Korea, while signs of an

Barclays raises its target to $39 as GLP-1 momentum builds and a peptide ruling approaches

FDA accepts RHHBY filing for Lunsumio VELO plus Polivy in relapsed or refractory LBCL as a potential chemotherapy-free treatment option.

PFE is betting on monthly obesity treatments and new oral programs to challenge LLY and NVO in a market projected to hit $120 billion by 2035.

Wegovy pill's U.K. approval gives Novo Nordisk its first European launch path ahead of wider EU approval as it seeks growth amid mounting pricing and competitive pressures.

Novo Nordisk (NYSE:NVO) is seeing strong uptake of its oral Wegovy treatment, with the tablet formulation accounting for roughly one-third of all Wegovy prescriptions by May, according to a Bank of America report published on Thursday. The data highlights the rapid adoption of the oral version since its market debut earlier this year and underscores continued momentum across the broader GLP-1 weight-loss drug market.

Barclays expects accelerating revenue and EBITDA growth in the second half of 2026, supported by weight-loss offerings.

Johnson & Johnson has no plans to enter the booming obesity market, opting instead to focus on diseases such as cancer, CEO Joaquin Duato said in an interview for an upcoming episode of The David Rubenstein Show: Peer to Peer Conversations. The comments set J&J apart from many of its rivals that are trying to develop or acquire obesity medicines following blockbuster weight-loss drugs from Eli Lilly & Co. and Novo Nordisk.

Healthcare stocks declined late Wednesday afternoon, with the NYSE Healthcare Index falling 1.3% and

Johnson & Johnson is focusing on oncology and neuroscience instead of obesity drugs, with AI possibly supporting its next growth cycle.

European stock markets closed mostly higher Wednesday as the Stoxx Europe 600 gained 0.5%, the Swiss

The group says it spent more than two months inside Novo Nordisk's networks, stealing over a terabyte of data including proprietary drug and AI information

Novo Nordisk (NYSE:NVO) has disclosed a patient data breach affecting individuals involved in its clinical trials. The company is assessing the scope of the data exposure and potential regulatory implications. At the same time, Novo Nordisk continues to face production capacity constraints for its GLP-1 therapies, including obesity treatment Wegovy. The combination of data security concerns and supply limitations raises fresh questions about operational resilience for the drug maker. Novo...

Novo Nordisk (CPSE:NOVO B) plans to seek Chinese regulatory approval for its oral Wegovy obesity pill. The planned filing would extend the company's weight loss franchise into China, a large potential market for obesity therapies. This move comes after prior focus on injectable Wegovy and recent attention on regulatory milestones in other regions, including the UK. Novo Nordisk, best known for its diabetes and obesity treatments, is pushing further into weight management with the oral...

CEO Doustdar expects to submit oral Wegovy for Chinese regulatory approval in "a few months"

Healthcare stocks edged higher Tuesday afternoon, with the NYSE Healthcare Index and the State Stree

These two healthcare leaders have a long history of competing against one another.

The European stock markets were modestly higher in Tuesday trading as the markets reacted positively

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

The move could expand Novo's reach in a key obesity-drug market.

Stocktwits data showed retail sentiment on SPY and QQQ has remained ‘bearish’ despite the recent rally.